Eyiol Hatice, Eyiol Azmi, Sahin Ahmet Taha
Department of Anesthesiology, Beyhekim Training and Research Hospital, Konya, Turkey.
Department of Cardiology, Beyhekim Training and Research Hospital, Konya, Turkey.
Medicine (Baltimore). 2025 Sep 12;104(37):e44460. doi: 10.1097/MD.0000000000044460.
Acute pericarditis is a sudden, typically noninfectious inflammation of the membrane surrounding the heart. It can arise from various causes, including viral infections, autoimmune diseases, cancer, trauma, or medications. This study aimed to evaluate the prognostic significance of the Pan-Immune-Inflammatory Value (PIV) and the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in predicting disease severity, recurrence, and prognosis in patients with acute pericarditis. A retrospective cohort study was conducted, including 281 patients diagnosed with acute pericarditis between 2014 and 2023. Data on hemoglobin, albumin, neutrophil, monocyte, lymphocyte, and platelet levels, as well as clinical characteristics, treatment outcomes, and recurrence status, were extracted from hospital records. The PIV was calculated using the formula: neutrophil count (10³/mL) × monocyte percentage (%) × platelet count (10⁹/L)/lymphocyte count (10³/mL). The HALP score was determined as hemoglobin (g/L) × albumin (g/L) × lymphocyte count (10³/mL)/platelet count (10⁹/L). Statistical analyses were performed to evaluate the associations between these biomarkers and clinical outcomes. PIV was significantly higher in patients with pericardial effusion, pericardial friction rub, and persistent chest pain at 15-day follow-up (P = .003). Patients with hypertension, hyperlipidemia, and recent infections showed elevated PIV values, indicating more severe disease and a higher likelihood of recurrence. HALP score was significantly lower in patients with pericardial effusion and in nonsmokers. HALP score was significantly higher in patients with electrocardiography changes. PIV emerged as a stronger predictor of pericarditis severity, prognosis, and recurrence compared to the HALP score. The combined use of both markers may enhance the assessment of disease severity and prognosis, offering valuable insights for clinical decision-making in pericarditis management. Further studies are needed to validate these findings.
急性心包炎是一种围绕心脏的膜的突发性、通常为非感染性炎症。它可由多种原因引起，包括病毒感染、自身免疫性疾病、癌症、创伤或药物。本研究旨在评估全免疫炎症值（PIV）和血红蛋白、白蛋白、淋巴细胞及血小板（HALP）评分在预测急性心包炎患者疾病严重程度、复发及预后方面的预后意义。进行了一项回顾性队列研究，纳入了2014年至2023年间诊断为急性心包炎的281例患者。从医院记录中提取了血红蛋白、白蛋白、中性粒细胞、单核细胞、淋巴细胞和血小板水平的数据，以及临床特征、治疗结果和复发状态。PIV使用公式计算：中性粒细胞计数（10³/mL）×单核细胞百分比（%）×血小板计数（10⁹/L）/淋巴细胞计数（10³/mL）。HALP评分确定为血红蛋白（g/L）×白蛋白（g/L）×淋巴细胞计数（10³/mL）/血小板计数（10⁹/L）。进行了统计分析以评估这些生物标志物与临床结果之间的关联。在随访15天时，心包积液、心包摩擦音和持续性胸痛患者的PIV显著更高（P = 0.003）。高血压、高脂血症和近期感染患者的PIV值升高，表明疾病更严重且复发可能性更高。心包积液患者和非吸烟者的HALP评分显著更低。心电图改变患者的HALP评分显著更高。与HALP评分相比，PIV成为心包炎严重程度、预后和复发的更强预测指标。联合使用这两种标志物可能会增强对疾病严重程度和预后的评估，为心包炎管理中的临床决策提供有价值的见解。需要进一步研究来验证这些发现。
